Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

Investors might want to bet on Takeda Pharmaceutical Co. (TAK), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Japanese drugmaker Takeda (TYO: 4502) posted revenue of 4.58 trillion yen ($31.7 billion) for the fiscal year ended March 31, ...

San Antonio’s H-E-B and other major retailers have teamed up to wage legal battles on both coasts against pharmaceutical companies for allegedly monopolizing the market for certain prescription drugs.

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Nektar Therapeutics’s NKTR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.

any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release ...